Journal
MABS
Volume 14, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2021.2020082
Keywords
developability guidelines; biopharmaceutical informatics; developability assessment; computational prediction; antibody engineering; therapeutic antibodies
Categories
Funding
- Engineering and Physical Sciences Research Council (EPSRC) via UK EPSRC [EP/N024796/1]
Ask authors/readers for more resources
This article provides an overview of antibody informatics tools for the prediction of developability issues and evaluates the opportunities and challenges of using biopharmaceutical informatics for drug discovery and optimization. Furthermore, it discusses the potential of developability guidelines based on in silico metrics.
Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly enabling the development of predictive models and computational tools for the developability assessment of antibody drug candidates. Here, we provide an overview of the antibody informatics tools applicable to the prediction of developability issues such as stability, aggregation, immunogenicity, and chemical degradation. We further evaluate the opportunities and challenges of using biopharmaceutical informatics for drug discovery and optimization. Finally, we discuss the potential of developability guidelines based on in silico metrics that can be used for the assessment of antibody stability and manufacturability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available